82F.F NFL BIOSCIENCES EO -03

Healthcare Biotechnology Frankfurt Exchange
0.3125 EUR
Close of Nov 11, 2026
0.2575 1.56
Market cap
EUR 3.96M
P/E
-
P/B
20.16x
ROE
-1,083.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 82F.F undervalued?

Graham number

The Graham number of NFL BIOSCIENCES EO -03 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NFL BIOSCIENCES EO -03 fundamental analysis

No fundamental analysis for NFL BIOSCIENCES EO -03 yet.

NFL BIOSCIENCES EO -03 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NFL BIOSCIENCES EO -03

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NF…

Full company profile